Source-grounded facts extracted from Harmony Biosciences Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Stephen Mollichella was appointed as Interim Principal Financial Officer at Harmony Biosciences Holdings, Inc..
“On July 16, 2026, the Board of Directors of the Company appointed Stephen Mollichella, the Company’s Senior Vice President and Controller, as Interim Principal Financial Officer of the Company, effective as of July 16, 2026.”
Glenn Reicin departed as Chief Financial Officer at Harmony Biosciences Holdings, Inc..
“On July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.”
Harmony Biosciences Holdings, Inc. shareholders approved Approval on a non-binding, advisory basis, of the compensation of the Company’s named executive officers at the 2026-05-14 meeting.
“Proposal 3. The approval on a non-binding, advisory basis, of the compensation of the Company’s named executive officers pursuant to the SEC’s compensation disclosure rules.”
Harmony Biosciences Holdings, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-14 meeting.
“Proposal 2. The ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Harmony Biosciences Holdings, Inc. shareholders approved Election of four Class III directors at the 2026-05-14 meeting.
“Proposal 1. The election of four Class III directors listed below to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.”
Harmony Biosciences Holdings, Inc. reported the quarter ended March 31, 2026 results: revenue $215.4 million. Guidance reaffirmed.
“BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz”
Ron Philip was appointed as Class III director at Harmony Biosciences Holdings, Inc..
“Effective April 2, 2025, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Ron Philip, age 51, as a Class III director, filling the previously announced vacancy in the Board created by the resignation of Jack Bech Nielsen effective June 27, 2024.”
Jeffrey Dierks departed as Chief Commercial Officer at Harmony Biosciences Holdings, Inc..
“Jeffrey Dierks will be departing from the Company as its Chief Commercial Officer, effective as of March 31, 2025 (the “Effective Date”), for personal reasons.”
Jack Bech Nielsen resigned as Director at Harmony Biosciences Holdings, Inc..
“On June 27, 2024, Jack Bech Nielsen notified the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) that he is resigning from the Board effective immediately, due to health reasons.”
Kumar Budur was appointed as Executive Vice President and Chief Medical & Scientific Officer at Harmony Biosciences Holdings, Inc..
“appointed Kumar Budur, M.D., M.S., the Company’s Chief Medical Officer, to the title of Executive Vice President and Chief Medical & Scientific Officer (the “Appointment”), effective on May 1, 2024”
Harmony Biosciences Holdings, Inc. reported Q1 2024 results: revenue WAKIX Net Revenue of $154.6 Million, net income GAAP net income for the quarter ended March 31, 2024, was $38.3 million, EPS $0.67 per diluted share. Guidance reaffirmed.
“ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES INTO RARE EPILEPSY WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward”
Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2023.
“On February 22, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”
Harmony Biosciences Holdings, Inc. reported 2024 results: revenue $700 million to $720 million. Guidance initiated.
“Expect full year 2024 net product revenue of $700 million to $720 million”
Harmony Biosciences Holdings, Inc. reported the full year ended December 31, 2023 results: revenue approximately $582 million. Guidance raised.
“Preliminary, unaudited net product revenue for the full year ended December 31, 2023, was approximately $582 million, compared to $437.9 million for the same period in 2022, representing ~33% growth”
Harmony Biosciences Holdings, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $168 million. Guidance raised.
“Preliminary, unaudited net product revenue for the quarter ended December 31, 2023, was approximately $168 million, compared to $128.3 million for the same period in 2022, representing ~31% growth”
Peter Anastasiou was appointed as Class III director at Harmony Biosciences Holdings, Inc..
“appointed Peter Anastasiou as a Class III director of the Company with an initial term expiring at the Company’s 2026 annual meeting of stockholders, effective immediately.”
Harmony Biosciences Holdings, Inc. completed an acquisition involving Zynerba Pharmaceuticals, Inc. for $1.1059 per Share in cash plus one contingent value right per Share (closed 2023-10-10).
“commenced a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Zynerba , par value $0.001 per share (the “Shares”), at a price of (i) $ 1.1059 per Share (the “Closing Amount”), in cash, subject to any applicable withholding of taxes and without interest, plus (ii) one contingent value right (each, a “CVR”) per Share ,”
Sandip Kapadia was appointed as Chief Financial Officer and Chief Administrative Officer at Harmony Biosciences Holdings, Inc..
“The Board of Directors of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Sandip Kapadia, the Company’s Chief Financial Officer, to the title of Chief Financial Officer and Chief Administrative Officer, effective upon Mr. Kapadia’s acceptance on September 30, 2023.”
Harmony Biosciences Holdings, Inc. amended First Incremental Amendment with Bank of America, N.A. valued at $15 million (effective 2023-09-21).
“On September 21, 2023 (the "Closing Date"), the Company, as borrower, entered into the First Incremental Amendment (the "First Incremental Amendment") with the Administrative Agent and Bank of America, N.A., as incremental lender. The First Incremental Amendment provides for an incremental senior secured term loan (the "Incremental Term Loan") in an aggregate principal amount of $15 million”
Harmony Biosciences Holdings, Inc. entered into Agreement and Plan of Merger with Zynerba Pharmaceuticals, Inc. (effective 2023-08-14).
“On August 14, 2023, Harmony Biosciences Holdings, Inc., a Delaware corporation (the “Company”) and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned, direct subsidiary of the Company (“Merger Sub”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Zynerba Pharmaceuticals, Inc., a Delaware corporation (“Zynerba”).”
Harmony Biosciences Holdings, Inc. reported quarter ended June 30, 2023 results: net income 34.3 million, EPS 0.56.
“Net product revenues for the quarter ended June 30, 2023 were $134.2 million, compared to $107.0 million for the same period in 2022.”
Harmony Biosciences Holdings, Inc. terminated Blackstone Loan with Blackstone Alternative Credit Advisors LP and the other lenders party thereto from time to time and Wilmington Trust, National Association, as administrative agent valued at $200 million (effective 2023-07-26).
“On July 26, 2023, upon entry into the New Credit Agreement described in Item 1.01 above, together with cash on hand, the Blackstone Loan was repaid in full, and all commitments thereunder were terminated.”
Harmony Biosciences Holdings, Inc. entered into New Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders valued at $185.0 million (effective 2023-07-26).
“On July 26, 2023 (the “Closing Date”), Harmony Biosciences Holdings, Inc. (the “Company”) entered into a Credit Agreement (the “New Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders. The New Credit Agreement provides for a five-year senior secured term loan (the “Loan”) in an aggregate principal amount of $185.0 million.”
Harmony Biosciences Holdings, Inc. shareholders approved Approval on a non-binding, advisory basis, of the compensation of the Company’s named executive officers as described in our proxy materials at the 2023-05-25 meeting.
“Proposal 3. The approval on a non-binding, advisory basis, of the compensation of the Company’s named executive officers as described in our proxy materials. Votes For Votes Against Abstain Broker Non-Votes 51,543,958 1,252,960 406,969 463,671 Based on the votes set forth above, the compensation of the Company’s named executive officers has been approved.”
Harmony Biosciences Holdings, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-25 meeting.
“Proposal 2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes For Votes Against Abstain 53,633,333 25,629 8,596 Based on the votes set forth above, the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was duly ratified.”
Harmony Biosciences Holdings, Inc. shareholders approved Election of three Class II directors to serve until the Company’s 2026 annual meeting of stockholders at the 2023-05-25 meeting.
“Proposal 1. The election of the three Class II directors listed below to serve until the Company’s 2026 annual meeting of stockholders and until their successors are duly elected and qualified. Votes For Withheld Broker Non-Votes Antonio Gracias 41,295,494 11,908,393 463,671 Jack Bech Nielsen 38,571,010 14,632,877 463,671 Andreas Wicki, Ph.D 37,229,122 15,974,765 463,671 Based on the votes set forth above, each of the director nominees was duly elected.”
Harmony Biosciences Holdings, Inc. reported quarter ended March 31, 2023 results: revenue $119.1 million, net income $29.5 million, EPS $0.48.
“--- Exhibit 99.1 HARMONY BIOSCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATES WAKIX® (pitolisant) Net Revenue Increased ~40% Year-over-Year to $119.1 Million for First Quarter 2023 Average Number of Patients on WAKIX Increased ~1,200 Year-over-Year to ~5,100 for First Quarter 2023 Exited First Quarter 2023 With ~5,200 Patients on”
Jeffrey S. Aronin changed role as non-executive Chairman of the Board at Harmony Biosciences Holdings, Inc..
“Jeffrey S. Aronin, who has served at the Company’s Executive Chairman since January 2023, has returned to his prior role as non-executive Chairman of the Board, effective April 24, 2023.”
Jeffrey M. Dayno was appointed as Class I Director at Harmony Biosciences Holdings, Inc..
“Dr. Dayno has also been appointed to the Board as a Class I Director”
Jeffrey M. Dayno was appointed as President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..
“Dr. Jeffrey M. Dayno, the Company’s current Interim President and Chief Executive Officer and Chief Medical Officer, has been appointed by the Board of Directors of the Company (the “Board”) as President and Chief Executive Officer (“CEO”) of the Company.”
Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2022.
“On February 21, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
John Jacobs resigned as other at Harmony Biosciences Holdings, Inc..
“in connection with Mr. John Jacobs’ resignation from the Company and the Board”
Jeffrey S. Aronin was appointed as Executive Chairman at Harmony Biosciences Holdings, Inc..
“the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.”
Jeffrey M. Dayno was appointed as Interim President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..
“the Board appointed Dr. Jeffrey M. Dayno as the Company’s Interim President and Chief Executive Officer (“CEO”), effective January 6, 2023.”
Jeffrey S. Aronin was appointed as Executive Chairman at Harmony Biosciences Holdings, Inc..
“On January 6, 2023, in connection with Mr. Jacobs’ resignation from the Board and to provide additional support and oversight during this transition period, the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.”
Jeffrey M. Dayno was appointed as Interim Chief Executive Officer at Harmony Biosciences Holdings, Inc..
“On January 6, 2023, the Board appointed Dr. Jeffrey M. Dayno, the Company’s current Chief Medical Officer, as the Company’s Interim Chief Executive Officer, effective January 6, 2023.”
John C. Jacobs resigned as President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..
“On January 6, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) announced that John C. Jacobs is resigning as President and Chief Executive Officer of the Company.”
Harmony Biosciences Holdings, Inc. reported the quarter ended September 30, 2022 results: revenue $117.2 million, net income $87.9 million, EPS $1.44 per diluted share.
“reference. --- EX-99.1 (EX-99.1) --- Exhibit 99.1 HARMONY BIOSCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATES WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,600 Prader-Willi Syndrome (PWS) Phase 2”
Linda Szyper was appointed as Class II director at Harmony Biosciences Holdings, Inc..
“Effective November 18, 2021, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Linda Szyper, age 56, as a Class II director”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.